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Title: Help-Seeking Beliefs Among Anabolic Androgenic Steroid Users Experiencing Side 1 
Effects: An Interpretive Phenomenological Analysis. 2 
Abstract: 3 
Recreational athletes comprise the most prevalent population using illegal Anabolic 4 
Androgenic Steroids (AAS) (Pope et al., 2014). Despite regulatory efforts, substances are 5 
widely accessible, and most users report the experience of harmful side effects. It remains 6 
unclear why few users seek professional medical help. The aim of this study was to determine 7 
AAS users experience of side effects and help-seeking beliefs using an Interpretative 8 
Phenomenological Analysis of six interviews. Participants were from the United Kingdom 9 
(n=5) and United States (n=1), had all experienced side-effects, with some reporting 10 
prolonged use of AAS (>10 years), and self-manufacturing the drugs from raw ingredients. 11 
Results showed that AAS users discredit medical professionals’ competencies, and practice 12 
cognitive dissonance by avoiding challenging situations. A microculture for information-13 
sharing has developed among AAS users who initially self-treat to counteract side effects, 14 
leaving them vulnerable to further harm. To conclude, there is an urgent need for educational 15 
interventions that outline the risky practice of unregulated AAS use and self-treatments, and 16 
the need to seek professional help. Such interventions could be developed through a co-17 
production basis, and be implemented by current/former AAS users alongside the medical 18 
community. 19 
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Title: Help-Seeking Beliefs Among Anabolic Androgenic Steroid Users Experiencing 24 
Side Effects: An Interpretive Phenomenological Analysis. 25 
Anabolic Androgenic Steroids (AAS) are hormones that comprise derivates of testosterone 26 
that regulate the development of male sexual characteristics (Aljubori, 2019). A substance 27 
can be defined as an AAS through the following criteria: (i) a chemical, or (ii) 28 
pharmacological compound that is related to testosterone, and (iii) not an estrogen, progestin, 29 
or a cortisol-based steroid (Goldman, Pope & Bhasin, 2018). The anabolic effects of AAS on 30 
physiological and psychological characteristics include abnormal fat and carbohydrate 31 
metabolism, increases in aggression and attention, and enhanced blood flow and up-regulated 32 
muscle protein synthesis (Yu, 2014). As such, AAS are efficacious in increasing muscular 33 
size, performance and aesthetics, and consequently, are prevalent in elite sport and 34 
professional bodybuilding (i.e., collective estimate of 13.4%; Sagoe et al. 2014). Surprising to 35 
most however recreational sportspeople (e.g., non-elite athletes, fitness clients) report the 36 
highest prevalence of illegal AAS usage at 18.4% (Petrocelli, Oberweis & Petrocelli, 2008). 37 
Therefore, research into this sensitive area has importance for public health providers (Pope 38 
et al., 2014). 39 
Given their anabolic functions, most countries permit medical prescription and clinical use 40 
of AAS for health conditions (e.g., severe sarcopenia), and therefore permit legal possession 41 
(Advisory Council on the Misuse of Drugs, 2010). An unintended consequence of this public 42 
health strategy has been the increasing public demand for AAS. Further, despite prohibition 43 
of AAS in commercial markets, underground sources (e.g., internet) facilitated an increased 44 
usage among the general population (Goldman, Pope & Bhasin, 2018). Indeed, a meta-45 
analyses by Sagoe et al. (2014) noted a lifetime prevalence rate of 3.3%, with 6.4% in males 46 
and 1.6% in females, with the conclusion that AAS use is a widespread public health concern. 47 




Researchers have established that many recreational athletes consume AAS for mostly 48 
cosmetic and personal image motives (e.g., improve lean body mass, reduce fat) and many 49 
AAS users conduct their own risk-benefit analyses, to the extent that the cosmetic benefits of 50 
AAS appear to outweigh the negative health risks (Kanayama and Pope, 2018). In contrast to 51 
recreational drugs (e.g., narcotics) typically encountered during adolescence, AAS is a late-52 
onset form of substance misuse (i.e., median=22 years of age) (Karazsia, Crowther & 53 
Galioto, 2013). Moreover, Pope et al. (2014) have argued that many AAS users may go 54 
undetected, largely because the side effects associated with AAS are considered negligible by 55 
many users.  56 
When self-administered without formal medical guidance, the use of AAS, especially from 57 
blackmarked sources, poses various physical and psychological risks (Perry and Hughes, 58 
1992; Iriarte and Andrade, 2002; Baggish et al, 2010). Existing regulatory efforts have failed 59 
to protect consumers by not accounting for the health threats posed by AAS (Goldman, Pope 60 
& Bhasin, 2018). Indeed, Aljubori (2019) outlined various physiological side effects ranging 61 
from heart hypertrophy to kidney failure, and deepened voice in women, and hypogonadism 62 
(i.e., reduced testosterone production) in men. Further evidence (Karazsia, Crowther & 63 
Galioto, 2013) suggests that mental health issues (e.g., depression, eating disorders) are 64 
associated with AAS use (Sagoe, Adreassen & Pallesen, 2014). It has also been found that 65 
AAS users often self-medicate with doses that far exceed medical norms (i.e., from 1000 up 66 
to 5000mg per-week), and engage in high-risk behaviours such as needle sharing (Goldman, 67 
Pope & Bhasin, 2018). Alarmingly, even when individuals are aware of information 68 
pertaining potential health harms of AAS, they often persist with their use (Walker & Joubert, 69 
2011; AlFalasi et al., 2008). To reduce engagement with such potentially harmful AAS use 70 




and their associated risks, it is necessary to understand the factors underpinning professional 71 
help-seeking behaviours among AAS users. 72 
The number of AAS users registered with advice services in the UK has increased in 73 
recent years, but the majority of users remain reluctant to engage with the available support 74 
(Evans, Brown and McVeigh, 2009; Interagency Drug Misuse Database, 2009). For instance, 75 
although recreational AAS users are registered with a General Practitioner (GP) as a first 76 
point of medical contact, GPs report a lack of help-seeking from AAS users (Lenehan, 2003). 77 
Grogan et al. (2006) reported that competitive bodybuilders may not seek help because of a 78 
lack of confidence in health professionals competencies, however this issue has yet to be 79 
explored with recreational athletes. Further, there remains a paucity of information on why 80 
most users do not seek help when they experience unwanted side effects, and what 81 
information and/or treatment strategies they use to self-manage (Yu, Hildebrandt & Lanzieri, 82 
2015). Indeed, the widespread availability of black market ‘stacks,’ that include unregulated 83 
substances to self-treat and counteract side-effects, presents further risk to the public 84 
(Goldman, Pope & Bhasin, 2018). Hence, there is a need for a research-informed 85 
understanding of the psychosocial factors that underpin professional help-seeking beliefs 86 
among AAS users (Grogan et al., 2006; Yu, Hildebrandt & Lanzieri, 2015). 87 
Given the lack of readily available interventions for populations implementing stigmatised 88 
practices in sport and exercise contexts (Breslin, Shannon, Haughey, Donnelly & Leavey, 89 
2017; McGuane, Shannon, Sharpe, Dempster & Breslin, 2019), Tamminen and Bennett 90 
(2017) advocate as an important initial step, the development of rich information through 91 
qualitative methodologies. In particular, Interpretative Phenomenological Analysis (IPA) is 92 
method that entails purposively selecting individuals, and providing participants with an 93 
opportunity to describe their unique subjective experience of personal and social phenomena 94 




in relation to the topic studied (Smith & Osbourne, 2003; Smith, 2004). Unlike other 95 
qualitative methodologies, IPA adopts a person-by-person, idiographic focus, and permits 96 
detailed insights on a topic that have not yet been explored (Larkin & Thompson, 2012). 97 
Given help-seeking is typically a unique and private experience, IPA can add value to 98 
understanding how social, cultural and psychological processes influence AAS use, and 99 
subsequent help-seeking behaviours. 100 
Therefore, the aim of the current study was to explore AAS use among recreational 101 
athletes and/or fitness clients, and specifically delve into the area of professional help-seeking 102 
for side effects. We sought to explore three key areas: (i) Users’ beliefs regarding the safety 103 
of AAS, and the information shared among peers; (ii) the treatments utilised and decision-104 
making processes involved in seeking professional help (or not); and (iii) possible routes to 105 
healthcare provision.  106 
Method 107 
Participants and Procedure 108 
The research was approved by Ulster University Research Ethics Filter Committee. We 109 
recruited participants through the Internet and by snowball sampling wherein participants 110 
recruited other hard to reach participants. Given the lower prevalence of, and difficulty in 111 
recruiting female AAS users outside of the bodybuilding subculture (Kimergard, 2015; Sagoe 112 
et al., 2014), only male users were approached for inclusion. Six males from the United 113 
Kingdom (n=5) and United States (n=1) agreed to participate (out of 7 approached), which 114 
adhered to the idiographic focus within Interpretative Phenomenological Analysis (IPA; 115 
Smith & Osborn, 2003). As part of our inclusion criteria we specifically sought recreational 116 
fitness clients and non-elite athletes who had experienced side-effects.  117 




Following ethical approval the primary investigator (PI) met the participants and 118 
outlined the study, highlighting that all responses would be anonymous. Under the guidance 119 
of two co-investigators with comprehensive experience in using IPA and qualitative 120 
methodologies, the PI collected data through semi-structured face-to-face interviews with 121 
each participant, at a convenient time and location. 122 
A semi-structured interview guide covering three broad areas was devised to ensure 123 
that a systematic line of inquiry was followed with each participant: (i) the experience and 124 
beliefs of using AAS, and side-effects experienced (ii) treatments for side effects and 125 
continuing/stopping using AAS; (iii) the experience of help-seeking. However, the interviews 126 
also ensured flexibility through allowing participants to spontaneously raise issues important 127 
to them (Smith & Osborn, 2003). Adhering to an IPA approach (Pietkiewicz & Smith, 2012), 128 
the PI conducted the interviews through a neutral and facilitative approach, providing 129 
participants with opportunities for reflecting on, and making sense of their experiences of 130 
AAS use and help-seeking attitudes/behaviours. Individual interviews lasted on average 60 131 
minutes and were transcribed verbatim. 132 
Data Analysis 133 
Participant’s accounts were analysed using IPA (Smith, Flowers and Larkin 2009; Smith and 134 
Osbourne, 2003). This method employed an idiographic multiple-case study approach to 135 
analysis, described by Smith (2004, p. 41) as a process that starts with: (i) “the detailed 136 
examination of one case study until some degree of closure or gestalt has been achieved”; (ii) 137 
continues with “a detailed analysis of the second case, and so on through the corpus of 138 
cases”; and (iii) moves on to “attempt to conduct a cross case analysis.”    139 




The authors (a sport and exercise psychologist, a Masters of Science student, a 140 
professor in health psychology, two PhDs in health psychology, and a General Practitioner) 141 
all had prior experience in using qualitative research methods. The PI transcribed each 142 
interview, and individually coded the data using close line-by-line coding to produce themes 143 
and subordinate themes (Larkin et al., 2006). To ensure quality and accuracy, the following 144 
steps were taken to ensure rigour (Tracy, 2010). First, two authors read and reviewed the PI’s 145 
coded data. The dependability of the findings was apparent in their agreement regarding the 146 
themes and sub-themes identified (Larkin & Thompson, 2012). Their findings were then 147 
formally discussed and debated among the research team, and cross-examined until 148 
consensus was reached. Once analyses was complete, extensive participant quotations were 149 
included in the text, such that readers have the opportunity to assess detail and develop their 150 
own conclusions (Tracy, 2010). Finally, all authors contributed to the writing and review of 151 
the article.  152 
Results and Discussion 153 
All participants were white males aged between 23 and 39 years old, and comprised a range 154 
of AAS users including recreational athletes (e.g., rugby) and fitness clients, who held 155 
various motives for use (e.g., cosmetic reasons, self-medication for self-diagnosis for low 156 
testosterone, gain size for their sport). Participant’s use of AAS varied between one period up 157 
to current and prolonged use for more than 10 years, with one participant reporting self-158 
manufacturing the drugs from raw ingredients. Participants had all experienced unwanted 159 
side effects. Table 1 below shows their demographic and contextual information.  160 
*** Insert Table 1 here***  161 




Overall, participants accounts were unique, highly contextualised, and detailed 162 
support for current evidence that unregulated AAS use can induce harmful physical and 163 
psychological side effects (Goldman, Pope & Bhasin, 2018; Aljubori, 2019). Moreover, users 164 
tended not to seek, or consider, professional help when presented with side effects, 165 
subsequently practicing personalised forms of risk-benefit analyses (Kanayama & Pope, 166 
2018), cognitive dissonance, and underground forms of self-treatment (Karazsia, Crowther, & 167 
Galioto, 2013). Whilst acknowledging that the present study comprised a small number of 168 
participants, and therefore findings are not widely generalisable, the results highlight an 169 
important need for, and important considerations in the development of educational 170 
interventions for recreational athletes and fitness individuals. Following the idiographic 171 
approach to analyses, comparisons between the participants resulted in four master themes 172 
developed from the data (i.e., a belief that GP’s and medical staff are ineffective; biasing 173 
harms and benefits; a subculture in facilitating and sharing information; maladaptive harm 174 
minimisation). Each master theme encompassed sub-themes that provided additional detail 175 
and insights into the participants individual and collective experiences. An overview of the 176 
findings are provided in Table 2, and a detailed summary and cross-comparison with extant 177 
literature is provided below.  178 
***Insert Table 2 here *** 179 
Master Theme 1: A belief that GPs and medical staff are ineffective 180 
Various assumptions about statutory health services and GPs embodied both a distrust 181 
and lack of confidence in their competencies regarding AAS. It was evident that there 182 
was a presupposition that presenting to a GP or medical professional will lead to the 183 
participant being challenged to reconsider their use of AAS for legal and health reasons. 184 




For instance, only P4 in the study fully disclosed their use to a medical professional, and 185 
this was not to their GP, and also not to the first Endocrinologist to whom he was 186 
referred to. Healthcare effectiveness hinges on trust and cooperation between patient and 187 
consultant (Mansfield, Addis, & Mahalik, 2003), and the perceptions of inadequate 188 
healthcare provision and legal stipulations, may therefore hinder levels of professional 189 
help-seeking. Such sentiments have also been expressed by professional bodybuilders 190 
(Grogan et al., 2006), and elite athletes (Kanayama & Pope, 2018), and this is one of the 191 
first studies to establish such beliefs among recreational athletes.  192 
        Specifically, participants emphasised the perceived inferior medical knowledge of 193 
health professionals in comparison to themselves, or that of their peers. For example, two 194 
participants outlined the following negative views of healthcare professionals:    195 
P2: “They have no…idea what’s going on, their level of knowledge is laughably 196 
poor… (with reference to endocrinologists), most will not actually acknowledge the 197 
role of estrogen in the male body.”  198 
P4: “Doctors are pretty ignorant when it comes to it… I spent the last year dealing 199 
with urologists and endocrinologists who are idiots. I knew the guy was wrong, so I 200 
asked for a second opinion. The thing is, any time I've spoken to endocrinologists 201 
they have referred to a book. I know they can't know everything, but if you have 202 
been referred to a specialist you want to know the person dealing with you is not 203 
just picking up some book that any old mong can pick up in a library. I've read 204 
those, I know all that stuff, I want someone who has practical knowledge of cases 205 
like these, and the nuances each individual has.” 206 




A further subtheme (unwillingness to disclose to the doctor; see Table 2) indicated that 207 
participants avoided any formal discussion of the side effects experienced with GPs. By 208 
generalising negative views of professional medical staffs’ knowledge regarding treatments, 209 
the participants could be viewed as practising cognitive dissonance. Cognitive dissonance is 210 
defined as altering one’s beliefs and behaviours to reduce the discomfort associated with 211 
conflicting or opposing information regarding one’s behaviours (Festinger, 1957). Authors 212 
(Newby-Clark, McGregor, & Zanna, 2002) have suggested a link between cognitive 213 
dissonance and negative emotions. In respect of our participants, cognitive dissonance may 214 
explain why they choose not to disclose to their AAS usage to GPs (e.g., P1 and P4). The 215 
findings expressed are reflective of attitudes held by competitive bodybuilders (Lenehan, 216 
2003; Karazsia, Crowther, & Galioto, 2013), such that, holding a prejudiced negative view of 217 
formal medical support means that seeking professional help is not an appropriate response. 218 
Inherent within the cognitive dissonance practiced, many of the participants also expressed 219 
an optimism bias regarding their ability to self-manage and consequently mitigate the 220 
unwanted side effects without the help of a GP. Within Optimism Theory (Shepperd, Patrick, 221 
Jodi, and Meredith, 2002), optimism bias refers to when people view their situation in a 222 
positive light and believe they are less likely than others to experience negative effects, and is 223 
mediated by increased perceptions of self-control (Shepperd, Patrick, Jodi, and Meredith, 224 
2002). In this context, through experiencing personal agency through seeking underground 225 
support (e.g., reading web discussion boards, speaking to peers), and then believing that they 226 
are more educated than formal medical staff, may have facilitated an optimism bias, and 227 
therefore further low levels of professional help-seeking (van Harreveld, van der Pligt, & 228 
Yael, 2009).  229 




Supporting Optimism Theory (Shepperd, Patrick, Jodi, and Meredith, 2002), P2, P3 and 230 
P4 displayed the greatest degrees of self-confidence in their knowledge about AAS use, and 231 
concomitant severest side effects (e.g., clinical depression). Such internal biases may have 232 
also facilitated a greater risk of underground forms of treatment, leaving users vulnerable to 233 
further harm (e.g., users reported taking ‘stacks’ of substances to counteract side effects) 234 
(Goldman, Pope & Bhasin, 2018). From a personality-focused perspective, the sentiments 235 
expressed by all but one of the participants (P6) regarding their superior knowledge of AAS 236 
may also suggest a degree of narcissism among recreational appearance-focused athletes, as 237 
is the case in professional bodybuilders (Pawłowska, Zaręba, & Potembska, 2016). 238 
Conversely, P6, who experienced a single negative side effect (i.e., heightened aggression), 239 
avoided further use of the substances and admitted being poorly educated, and described how 240 
he followed his coach’s advice to use AAS because of his self-confessed inadequacies.  241 
All participants held the view that disclosure to a GP or medical professional would be 242 
met by a verbal reprimand and/or that the GP would patronise or sneer at the patient in this 243 
scenario. The colloquialism of “looking down their nose at you” was used explicitly by P1 244 
and P2, suggesting an anticipated moralising aspect of the clinical encounter. In this view, 245 
when GP inquired about their use of drugs, participants felt a prejudiced form of stigma. 246 
These findings align with extant research (Yu, Hildebrandt & Lanzieri, 2015) indicating a 247 
prejudiced view of AAS users among healthcare providers, when in comparison to their 248 
views of other drug users. Indeed, to improve such engagement between the communities, 249 
Anawalt (2019) among others (Creado & Reardon, 2019) have emphasised a compassionate, 250 
and patient-centred approach from practitioners, such that self-efficacy is encouraged during 251 
periods of resistance.  252 
Master Theme 2: Biasing harms and benefits 253 




The side effects reported among our participants support studies (Parkinson & Evans, 2006), 254 
indicating that the vast majority (99.2%) of users report harmful side effects from AAS use. 255 
In this regard, the second master theme highlighted confirmation bias on the effects of AAS 256 
use. Confirmation bias permits a selective attention paid to information which supports a 257 
person’s beliefs, and the subsequent overlooking of information which challenges a person’s 258 
beliefs (Lord, Ross, Lepper, 1979). The confirmation bias expressed by our participants was 259 
evident in their belief that AAS use was safe, and allowed them to achieve personal goals. 260 
For instance, P2 stated that AAS helped him gain education, and encouraged him to maintain 261 
an active, healthy lifestyle, whilst also listing sixteen adverse side effects experienced 262 
through AAS use. This ‘bracketing off’ for serious risk factors ensured that confirmation bias 263 
is used as a strategy to prevent the discomfort of dissonance (van Harreveld, van der Pligt, 264 
and de Liver, 2009). Thus, confirmation bias differs from feelings of ambivalence, in that 265 
ambivalence is holding conflicting attitudes towards a subject (Cooper, 2007).  266 
In another example of ‘bracketing off’ potential harms, P2 noted that he suffered from 267 
cysts to his liver, yet also mocked the notion of steroids causing liver cancer. Likewise, P3 268 
stated that they experienced few serious issues, and confirmation bias appears evident in his 269 
self-diagnosis and self-treatment, as indicated below. 270 
P3: “As far as serious issues go I've never really heard of any serious issues and 271 
it’s not like it's something you can overdose on. Unless you get an infection and 272 
you leave it too long and it goes septic, you are not going to die…There was 273 
about a three week period where I was lactating, but that cleared up as soon as 274 
I handled the side effect. Everything I have encountered can pretty much be 275 
avoided if you know how to handle it.”  276 




This biased rationalisation process is again drawn with P6, who stated that he does not: 277 
 P6: “do any drugs, and drinks at the most three times per year” 278 
Because participants displayed a sense of control and personal knowledge of AAS, 279 
participants displayed confirmation bias regarding their self-categorisation as a sensible ‘drug 280 
user’, rather than an ‘drug abuser’. For instance, P2 made the distinction that, while the 281 
medical community would stigmatise him an abuser, he would consider himself a responsible 282 
user. This perspective is supported in one of the few qualitative studies among recreational 283 
athletes (Kimergard, 2015), in which users tend to ignore the potential harms of risky 284 
behaviours, and rather, convey their control and strategic risk management. Lastly, all 285 
participants expressed a degree of scorn towards uneducated users whom they deemed 286 
irresponsible. As such, there appears to be converging evidence that recreational users tend to 287 
minimise, or ignore problems and emphasise their ability to cope (Monaghan, 2001; 288 
Petrocelli, Oberweis & Petrocelli, 2008; Kimergard, 2015). A biased rationalisation process 289 
allows individuals to pursue muscular performance and appearance goals.  290 
Master Theme 3: A subculture in facilitating and sharing information  291 
The participants consistently reported a sense of belonginess to a microculture which 292 
transfers knowledge about AAS usage, and sustains beliefs and norms. The presence of such 293 
dynamic social processes also aligns with components of Social Identity Theory (SIT; Tajfel, 294 
1982), to the extent that individuals practice ‘in group’ hidden attitudes, norms and 295 
behaviours, that ‘out groups’ are not privy to. Indeed, studies (Dunn, Mazanov & Sitharthan, 296 
2009) have indicated that being acquainted, or friendly with other AAS users significantly 297 
predicted future intentions to use AAS. Several participants recommended the documentary 298 
‘Bigger Stronger Faster’ (Bell, 2008) to other users, and cited the documentary as a 299 




foundation for their information, and motives to pursue usage of steroids. A common 300 
rationalisation for this view, specifically articulated within the documentary ‘Bigger, Faster, 301 
Stronger’, is that AAS  are not as harmful as other more common substances such as alcohol 302 
and tobacco. Indeed, and through a confident demeanour, P1, P2, P5 and P6 all outlined that 303 
AAS can be used safely and has many positive medical benefits, with P1 specifically stating 304 
that AAS is not in the top 100 of reasons patients are admitted to emergency rooms, whilst 305 
alcohol and tobacco rank higher (n.b. the documentary used unadjusted statistics for 306 
population usage of AAS).  307 
An additional sentiment displayed by the participants was that they belonged to a 308 
subculture that held ‘insider’ knowledge with regard to accessing AAS, dosages, correct 309 
formulation of ‘stacks’ of substances, and being privy to information that is exclusive to the 310 
culture. Our findings therefore support extant evidence among recreational athletes 311 
(Petrocelli, Oberweis & Petrocelli, 2008; Kimergard, 2015), indicating a dissemination of 312 
private knowledge among experienced and inexperienced users. Further, all our participants 313 
cited the internet as a pertinent source of information, and as an accessible way to 314 
‘underground’ markets.  315 
Specifically, three participants used the same forum, while one used multiple forums, 316 
and cited the benefit that these internet forums ensure anonymity and allow for people to ask 317 
questions and receive answers on the use of AAS. Research (Cordaro, Lombardo & 318 
Cosentino, 2011) has indicated that unregulated internet sources often recommended doses 319 
that are two–fourfold higher than current medical norms, and further work (Clement et al., 320 
2012) has proposed that less than 5% of websites provided accurate health information 321 
regarding steroids. Such misinformation among forums and product websites, may have 322 
provided our participants with greater perceived knowledge, and therefore a greater risk of 323 




engaging with maladaptive help-seeking behaviours because of optimism and confirmation 324 
bias.  325 
Master Theme 4: Maladaptive harm minimisation  326 
The final theme relates to ‘harm minimisation’, which occurred as a maladaptive form of 327 
self-treatment and help-seeking. The most pertinent finding of this study is that almost all 328 
(5/6) participants attempted to self-treat with other substances following their self-diagnosis 329 
of side effects. This maladaptive response to harm minimisation ties further with the control 330 
aspect of optimism bias, such that self-diagnosing and self-treating is a further control-331 
seeking behaviour (Shepperd, Patrick, Jodi, & Meredith, 2002). These behaviours 332 
demonstrate cause for concern, as the self-treatment of symptoms without medical formal 333 
supervision from a medical professional is a risky practice (Cordaro, Lombardo & Cosentino, 334 
2011; Clement et al., 2012). Furthermore, a polypharmacy of AAS use with other illicit 335 
substances has been found to induce harmful psychophysical effects (Sagoe et al., 2015). 336 
Specifically. we found that five of the participants have treated themselves for side effects 337 
with substances and methods found illegally on the ‘black market’. Substances ranged from 338 
the use of tamoxifen to combat gynaecomastia, to the act of bloodletting through a peristaltic 339 
pump to relieve symptoms of high blood pressure and polycythaemia (P2). Critically, at the 340 
first sign of trouble, the usual response is self-treat and, failing that, to find someone in the 341 
social network to ‘fix’ them, as stated by P6. The following statement by P4 further outlines 342 
the maladaptive cycle of information sharing, and underground forms of self-treatment 343 
among AAS users, which ultimately exposes them to further potential harm;  344 
P4: “The more convinced you are that you know better, then more likely you are 345 
to self-medicate.” 346 




In contrast to a qualitative study among recreational AAS users in the UK (Kimergard, 347 
2015) none of our participants reported contact with formal harm reduction services. From an 348 
intervention production standpoint, existing health harm reduction services have been largely 349 
top-down focused (i.e., expert led) rather than consumer-led (Filipe, Renedo & Marston, 350 
2017). Importantly, the lack of stakeholder involvement into such interventions can often 351 
result in a perceived lack of trust and confidence among potential participants, and thus lack 352 
of subsequent engagement, which may have been the case for some of our participants.   353 
Non-AAS drugs such as fat burners, and ‘stacks’ that included multiple unregulated 354 
substances to counteract side effects, were also consumed by the participants. Our findings 355 
thus corroborate a meta-synthesis of existing studies (Sagoe et al., 2015) that highlighted an 356 
association of AAS use with other illicit drugs. Several participants also indicated the usage 357 
of recreational drugs (e.g., P3), who indicated that while AAS may be viewed as: 358 
P3: “bad…so is the bottle of whisky (I) washed it down with”  359 
Interestingly, the data also revealed some harm minimisation practices which could be 360 
considered more adaptive. For example, P5 who was the most reluctant user identified, stated 361 
being aware of aggression and irritation during his AAS use, and indicated seeking a greater 362 
ability to be calmer by reducing and stopping AAS use. P2 also reported that when he used 363 
trenbolone he informed his partner of mood changes, perceived by him as minimising the 364 
potential damage to social connections.  365 
Clinical implications 366 
The aims of this study were to understand AAS users’ help-seeking beliefs from medical 367 
professionals, and their experience of, support sought, and treatments used for AAS-induced 368 
side effects. Findings support recent evidence that AAS use is a widespread public health 369 




issue (Sagoe et al., 2014), and existing regulatory efforts have failed to account for the health 370 
threats posed by AAS (Goldman, Pope & Bhasin, 2018), demonstrating a clear need for 371 
interventions among the present population. Given the small sample size, findings should be 372 
interpreted with caution. However, the flexible IPA approach (Smith & Osborn, 2003) 373 
yielded valuable and detailed insights which unearthed various novel findings regarding AAS 374 
users’ beliefs, and may translate into policy, research and clinical practice.  375 
Specifically, our findings showed that AAS users who experience side effects are likely to 376 
self-diagnose and self-treat, because: (i) they believe that GPs and professional medical staff 377 
are ineffective and lack knowledge of AAS; (ii) users’ bias harms and benefits of AAS, and 378 
practice cognitive dissonance by avoiding situations in which their views can be challenged; 379 
(iii) a subculture facilitates and shapes an ill-informed discourse that AAS side-effects can be 380 
safely self-treated, and; (iv) unregulated pharmacological forms of self-treatment (e.g., 381 
stacks) are widely accessible through the black market, which are often advocated for by 382 
experienced users. Subthemes revealed that the perceived inferior knowledge of the formal 383 
medical community is reinforced by pro-steroid information sources (e.g., internet, peers), 384 
and builds a greater perceived sense of self-control in line with the theory of optimism bias. 385 
This pathway to increased control is further facilitated through the practicing of cognitive 386 
dissonance and confirmation bias. These master and sub-themes are interlinked, and all 387 
present challenges for the medical profession to overcome.  388 
In order to curb the increasing rates of harmful and unregulated AAS use, further on-going 389 
government funding and support should be given towards nationwide prevention schemes 390 
and AAS awareness training (Evans, Brown & McVeigh, 2009). In this vein, free and 391 
confidential screening, and help-seeking advice could be made available through fitness 392 
centres, sports clubs, health centres and online mediums (Reardon & Factor, 2010). It is 393 




recommended that focus be given towards treatment and prevention strategies in order to 394 
disrupt the established negative cycle of AAS initiation and subsequent dependence, 395 
withdrawal and relapse (Goldman, Pope, & Bhasin, 2018). Such services could be founded 396 
on the optimistic view that most reported side-effects are treatable, and often reversable 397 
through existing formal medical care (Anawalt, 2019).   398 
Our study, among others (Karazsia, Crowther, & Galioto, 2013), highlighted that the 399 
interactions between medical professionals and clients will be crucial to effective delivery of 400 
such programmes, to the extent that prejudice to one another is common among both medical 401 
professionals AAS users (Yu, Hildebrandt & Lanzieri, 2015). Therefore, from a healthcare 402 
systems perspective, we recommend practitioners and clinical health providers adopt a client-403 
centred approach during counselling, education and communication of awareness messages 404 
(Crawford, Brown, Kvangarsnes, & Gilbert, 2014). Such approaches can support clients’ 405 
needs through active listening, provision of opportunities for client input, regular positive and 406 
constructive feedback, and consistent encouragement for patients to take an active role in the 407 
care they are receiving alongside the healthcare providers (Ryan & Deci, 2017).   408 
Client-centred care has been shown to be more effective when interventions are designed 409 
and implemented through a co-production basis that integrates all of the relevant stakeholders 410 
from the outset (e.g., patients, counsellors, recruitment officers, policy makers) (Palumbo, 411 
2016). Co-production efforts could invite current and/or past AAS users to design and 412 
implement programmes alongside formal medical providers. Such interventions could also 413 
include case studies on the misinformation conveyed by unregulated black-marketed sources, 414 
in addition to harmful side-effects and routes to non-stigmatising healthcare (Palumbo, 2016). 415 
It is proposed that over time such efforts may lead to consumer-driven prevention efforts, 416 
which can be seen in other domains (e.g., smoking; Hawkins et al., 2017). However, it is 417 




important to state that given evidence-based harm reduction and treatment programmes 418 
remain to be developed for the recreational athlete population, ongoing and cautious effort 419 
should be spent during programme development and refinement, in order to ensure feasibility 420 
and acceptability (Breslin et al., 2017; Oliver, Kothari & Mays, 2019). 421 
Lastly, it is evident that research on specific harm reduction services and psychiatric 422 
approaches to treatment is lacking among athletes (Creado, & Reardon, 2016). Hence, co-423 
production interventions should involve regular and reflective research practice, wherein all 424 
stakeholders agree on the research questions, collection and interpretation of data, and 425 
recommendations on further therapeutic approaches (Oliver, Kothari & Mays, 2019). We 426 
hope that that the present study contributes further insight into the experiences of AAS use 427 
among recreational athletes, and ultimately contributes to harm reduction of AAS and 428 
associated behaviours. 429 
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